← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Revagenix, Inc.
San Mateo, CA
$40,209,479
Total funding
2
Grants
Funding over time
peak $17.9M · FY2020–24$20M$15M$10M$5M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$40,209,479 · 2
By mechanism
N01$40,209,479 · 2
Investigators at Revagenix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases$11,270,810
N01 · FY2024 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$6,662,439
N01 · FY2022 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$6,642,016
N01 · FY2024 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$5,121,040
N01 · FY2023 · AI
A NOVEL THERAPEUTIC WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY$4,798,925
N01 · FY2022 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,982,520
N01 · FY2020 · AI
Development of Therapeutic Products for Antibiotic Resistant Bacteria$2,731,729
N01 · FY2021 · AI